Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged >6 Years with Cystic Fibrosis and at Least One F508del Allele A Phase 3, Open-Label Clinical Trial

Claire Wainwright, Susanna A. McColley, Paul McNally, Michael Powers, Felix Ratjen, Jonathan H. Rayment, George Retsch-Bogart, Erica Roesch, Neil Ahluwalia, Anna Chin, Chenghao Chu, Mengdi Lu, Prema Menon, David Waltz, Tanya Weinstock, Laura Zelazoski, Jane C. Davies

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged >6 Years with Cystic Fibrosis and at Least One F508del Allele A Phase 3, Open-Label Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences